Here, we address the question whether the dominant role of p53/p21CIP1 activation for DNA-damage-induced senescence can also be observed upon treatment with oxaliplatin in colorectal carcinoma (CRC) cell lines. This evidence concerns the gene TP53 and colorectal carcinoma.